

# MICHAEL SCHMÜCK-HENNERESSE

Group Leader Immune System | Nominee Non-Voting Member



## Scientific Development / CV:

- 2008-2012 - Doctoral candidate, Charité, Institute for Medical Immunology
- 2013-2017 - Post-Doctoral Researcher, Charité – Universitätsmedizin Berlin
- 2014 - Post-Doctoral Researcher, Baylor College of Medicine Houston, TX, USA
- 2017-2019 - Junior Group Leader `Experimental Immunotherapy´ at the BCRT
- Since 2020 - Group Leader `Experimental Immunotherapy´ at the BCRT, platform immune system

## Expertise:

- T cell biology in autoimmunity, transplantation and cancer, immune monitoring
- CRISPR-Cas-mediated targeted gene modification of T cells
- Since 2012 mentoring of 11 PhD students, 4 Master and 2 Bachelor students, since 2012 lecturer at Charité and Beuth

## Relevant Projects / Highlights:

- Intra-tumoral CXCR3 chemokine system for response prediction in solid tumor disease. Development of an advanced immunotherapeutic approach funded by the BMBF: A Chemokine Checkpoint Accelerant (**CONAN**, 2.5 MioEUR)
- Next generation regulatory and antigen-specific T cell products (funding: European H2020 RIA RESHAPE (200tEUR) and BCRT research focus regenerative Medicine BCRT - Crossfield TEFF, 225tEUR/a)
- Immunopathology issues related to CRISPR-Cas-mediated gene editing (funding: BIH grant, 100tEUR)
- Development of cell-based therapy products (ATMPs: within the GMP pipeline)

## Selected last-authorships since 2019 / patents:

- *CRISPR-Cas-edited Tacrolimus-resistant antiviral T-cells for advanced adoptive immunotherapy in transplant recipients. **Molecular Therapy**, 2020 (Cell press, IF 9.2, in press)*
- *The Intra-tumoral CXCR3 Chemokine System for Response Prediction of Chemotherapy in Human Bladder Cancer. **Science Translational Medicine**, 2020 (IP 16.3, pre-accept)*
- *High prevalence of *S. pyogenes* Cas9-reactive T-cells within the adult human population. **Nature Medicine**, 2019 (IF 36.1)*
- 7 patent applications, 1 IP filed

# MICHAEL SCHMÜCK-HENNERESSE

Group Leader Immune System | Nominee Non-Voting Member



## ‘Connecting through science’

### Overarching aims for the BCRT:

- Cross-linking the BCRT and the BeCAT
- Making the BCRT a *Berlin brand*!
- Developing further the BCRT into an (immunological) translational hub
- Acting - as a non-voting member - as a connecting link between PhD students and the steering committee
- Appointing an ombudsman for students of the BCRT

### **Aspiration:**

- Encourage and strengthen interaction of scientists within the BCRT
- Implement a PhD faculty of all students of the Cranach house

### Aims for the platform:

- Immunology as an integrated and central topic within the BCRT
- Installment of a monthly PhD seminar series: informal progress report from PhD students, profit from interdisciplinary input, presentation of "real" data including negative results, no glossy show, *no PIs*.